The European Treatment Outcome Study (EUTOS) investigated the treatment and treatment outcome of patients with chronic myeloid leukaemia (CML).
Data of 2904 newly diagnosed CML patients in 20 countries or prespecified regions of Europe were recorded in a web-based registry. 94% of patients were diagnosed in early stage of disease and received treatment with imatinib according to the European LeukemiaNet (ELN) recommendations. Newer treatment options were used by patients in clinical trials or with chromosomal abnormalities. Sub-standard treatments were used rarely, but mainly in older patients. Patient survival probabilities were similar to clinical trial results after adjusting to risk profile.
Presented by Fr. Dr. rer. biol. hum. Verena Hoffmann, BSc, MA, Ludwig-Maximilians-Universität München, Germany, at the 20th Congress of the European Hematology Association (EHA).
